Design and characteristics of a cavity-enhanced Fourier-transform spectrometer based on a supercontinuum source.

We report the in-house fabrication of a high-resolution Fourier-transform spectrometer (FTS) for the spectroscopy of molecules in the gas phase at resolutions down to 0.002 cm-1 working in the spectral range from 5880 cm-1 (1.7 µm) to 15 380 cm-1 (650 nm). The FTS employs a supercontinuum as a broadband light source and a He:Ne laser with a homemade frequency-stabilization scheme as the spatial reference for the sampling of the interferogram on a constant optical path difference (OPD) grid. The sampling of the two lasers is performed at constant time intervals, and the resampling process is performed at the software level. The resampling of the interferogram on a constant OPD grid relies on cubic approximations of the He:Ne interference pattern to determine its zero-crossings. The use of an invariant in the sampling process allows us to perform on-the-fly data treatment. Both the hardware aspect and the data processing are described with, in each case, an original approach. We also report the successful coupling of the FTS with a high finesse optical cavity with effective mirror reflectivities of 99.76%, allowing us to reach sensitivities down to 6.5 × 10-8 cm-1 with a root-mean-square accuracy of 0.0017 cm-1 on the position of the Doppler-broadened transitions with a mean transition width of 0.046 cm-1 for spectra recorded at a spectral resolution of 0.015 cm-1. The sensitivity of the instrument per spectral element, once normalized, represents the best sensitivity reported in the literature for Fourier-transform incoherent broadband cavity-enhanced absorption spectroscopy with a supercontinuum light source.

Specific testing for "isolated" anti-52 kDa SSA/Ro antibodies during standard anti-extractable nuclear antigen testing is of limited clinical value.

AIM: To ascertain whether specific testing for "isolated" anti-52 kDa SSA/Ro antibodies (a-SSA/Ro52) during standard anti-extractable nuclear antigen (ENA) testing is clinically useful. METHODS: 1438 consecutive sera submitted for anti-ENA testing over 1 year were evaluated for a-SSA/Ro52 using various assays. RESULTS: 7 of 1438 (0.48%) patients were found to have a-SSA/Ro52 without SSA/Ro60 antibodies. Subsequent testing detected a further five patients. Clinical follow-up was possible in 10/12 patients. 2 of these 10 patients had evidence of primary Sjögren's syndrome (SS) and one had systemic lupus erythematosus (SLE), with sicca symptoms and abnormal Schirmer's tests. Five other patients had sicca symptoms, of which four had abnormal Schirmer's tests. CONCLUSIONS: "Isolated" anti-52 kDa SSA/Ro antibodies were detected in approximately 0.5% of standard anti-ENA requests, in which their presence was generally not associated with underlying SS or SLE. In view of the increased testing complexity and costs in detecting and confirming these antibodies, specific testing for isolated a-SSA Ro52 antibodies during standard anti-ENA testing seems to be of limited clinical value in a non-obstetric population.

13C-N.m.r.-spectral study of the mode of binding of Gd3+ to various glycopeptides.

Natural-abundance, 13C-n.m.r. spectroscopy was used to study the mode of binding of Gd3+ to mono-O-glycosylated L-serine and tripeptides variously composed of Gly and L-Thr. When the amino and carboxyl groups of the amino acid are not blocked, strong interaction of Gd3+ with them is observed; this is also readily apparent with some related, nonglycosylated peptides. When the amino and carboxyl groups of the amino acid are blocked, noticeable interaction of Gd3+ with the glycosidic oxygen atom (O-3) and O-2' for the glycopeptide containing alpha-D-Galp, and with O-3 and N-2' for the glycopeptide containing alpha-D-GalpNAc, is observed. Weak interactions are also possible with O-4' and O-6' of the glycosyl groups. Although the amino acids were protected, these metal ion-carbohydrate interactions may still be mediated, to some extent, by the acetyl protecting the amino group and by the ester group on the amino acid.

Possible role of the carbohydrate residues in the display of the MN blood group determinants by glycophorin A.

Heterozygous glycophorin AM,N and homozygous glycophorin AM were reductively methylated with 13C-enriched formaldehyde in the presence of cyanoborohydride. Total reductive methylation modified the five lysine residues, and the N-terminal amino acid residues (serine and leucine) of glycophorins AM and AN, respectively. The 13C resonances of the incorporated labels were monitored as a function of the degree of glycosylation of the glycoprotein. While minimal, if any, structural changes were observed near the N-terminal amino acid upon removal of alpha-D-N-acetylneuraminic acid residues, gross structural changes were observed when most of the oligosaccharide chains were removed. We also found that progressive methylation of the lysine residues of glycophorin AM may influence either the chemical shift of one of the nonequivalent methyl groups of the N alpha, N-[13C]dimethyl serine residue, or one of the two states of glycophorin AM.

13C-N.M.R.-spectral study of the binding of Gd3+ to glycophorin.

Natural-abundance, 13C-n.m.r. spectroscopy was used to study the binding of Gd3+ to glycophorin, and also to the tetrasaccharides isolated from glycophorin after treatment of the glycoprotein with NaOH-NaBH4. Gd3+ binds to the tetrasaccharide (both in the isolated, reduced form and when still attached to the native glycoprotein), and, especially, to the alpha-NeuAc residues. In order to cause severe line-broadening of the 13C resonances of alpha-NeuAc, the ratios of the alpha-NeuAc residues of glycophorin, and of the isolated, reduced tetrasaccharide, to Gd3+ were much higher than that needed for causing similar broadening for 2-O-methyl-alpha-NeuAc-Gd3+ solutions. These results indicate that the other carbohydrate residues of the tetrasaccharide may be involved in the binding of Gd3+, producing a stronger metal-ion-binding effect.